The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | GMMG-DANTE: DVd in patients with multiple myeloma and renal impairment
Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, briefly discusses the Phase II GMMG-DANTE trial (NCT02977494), which investigated the combination of daratumumab, bortezomib and dexamethasone (DVd) in patients with multiple myeloma and renal impairment. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory role/honoraria: GSK, Sanofi, Janssen, Bristol Myers Squibb/Celgene
Research support: AbbVie, GSK (both to the institution)
Travel support: Sanofi
Other (travel support, training): GSK, Sanofi, AbbVie
